Tagged with research

France Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet goes on to elaborate on the cluster’s extensive scientific offering and his ambitions to build a collaborative network of life…

Opinion Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan’s Asia Pacific office, outlines the technological innovations currently driving the drug development pipelines of rare disease companies.   Recent advancements in the development of novel platforms for precise targeting of small molecules, gene therapy, stem cell therapy,…

Korea Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within…

Korea Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive director, Jae Cheon Yeo, explains the crucial role the organization plays in promoting R&D in Korea, the evolution of the…

China Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the growth of the biotech and pharma industries; the cutting-edge solutions and technologies Cell Signaling Technology is committed to providing to…

Spain Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the reasons for the boom in Spain’s clinical trials ecosystem, and the importance of a close-knit client-to-service-provider relationship for CROs today.   We are the first Spanish company…

China Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their…

Spain Alfonso García Cañamaque, CEO of León Research, gives an overview of the Spanish clinical research ecosystem and the challenges facing CROs. Also, he explains the differentiating factor of the company and internationalization strategy moving forward as they position themselves as the partner of choice.   One of our challenges is…

Spain Albert Barberá, director general of research and innovation in health for the Government of Catalonia, highlights his top priorities to facilitate the growth of the Catalan innovation scene and how he plans to transfer this to the healthcare system. Furthermore, he explains the importance of providing smaller companies with the…

Korea Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its technological platform to differentiate itself from the other international CROs conducting global studies in Korea.   Korea manages to combine…

Spain Cristina Garmendia, president of the Cotec Foundation, gives an overview of the innovation landscape in Spain and the steps needed to see this grow in the future. Furthermore, she gives advice based on her experiences with Genetrix, a company recently sold to Takeda, and she highlights what is next in…

China While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and modulating the glucokinase enzyme. The company is now applying the same principles to develop treatments for CNS disorders. Hua Medicine’s…